AUSTIN, Texas — Vermillion, Inc. ((NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its third quarter financial results on Thursday, November 10, 2016, followed by an investor conference call and webcast at 4:30 p.m. (ET).
Thursday, November 10th @ 4:30 p.m. (ET)
Conference ID: 6709878
Replay dial-in numbers (available through): November 24, 2016
Replay PIN: 6709878
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with debilitating diseases. The company's initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity, optimized platform and ease of use . For additional information, including published clinical trials, visit www.aspirawh.com.
Investor Relations Contact:
LifeSci Advisors LLC